Sobi Acquires Arthrosi Therapeutics

Sobi Acquires CTI BioPharma Corp.

June 26, 2023

Biotechnology

Swedish Orphan Biovitrum AB (Sobi) completed the acquisition of CTI BioPharma Corp. through a cash tender offer and subsequent merger, paying USD 9.10 per share for a transaction valued at up to USD 1.7 billion. CTI, a Seattle-based biopharmaceutical company with the FDA-approved product VONJO and ~144 employees, becomes an indirect wholly owned subsidiary of Sobi and will be delisted from NASDAQ.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

Juvisé Pharmaceuticals Acquires Ponvory (ex-US/Canada) from Actelion; Bpifrance and Pemberton Invest in Juvisé

March 26, 2024

Pharmaceuticals

Juvisé Pharmaceuticals has acquired global commercial rights (excluding the United States and Canada) to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson company. To fund the transaction, French sovereign fund Bpifrance and private credit manager Pemberton Asset Management took minority stakes in Juvisé; Juvisé will commercialize and assume manufacturing duties for Ponvory in Europe.